Core Viewpoint - The company is focused on maintaining a stable profit distribution policy while considering future dividend plans based on various factors such as business performance and regulatory requirements [1] Group 1: Company Performance and Strategy - As of October 14, 2025, the company's stock price closed at 22.31 yuan, down 1.2%, with a turnover rate of 1.57% and a trading volume of 61,100 shares, amounting to a transaction value of 137 million yuan [1] - The company has received approval for its companion diagnostic products to be used with Merck's MET inhibitors in the Chinese and Japanese markets, indicating a strategic partnership with a major pharmaceutical player [1] - The company emphasizes the importance of investor returns and is open to suggestions regarding dividend policies, which will be evaluated by the board based on the company's development stage and financial needs [1] Group 2: Industry Context and Competitive Position - The company is positioned within a growing market for high-end medical equipment, benefiting from national policies promoting domestic production and import substitution [2] - The company has developed a comprehensive sequencing technology platform, including the Salus Pro gene sequencer, which received regulatory approval as a Class III medical device in January 2025 [2] - The collaboration with SaiLu Medical aims to leverage the strengths of both companies in sequencing technology and tumor gene detection, enhancing long-term competitiveness in the industry [2] Group 3: Market Activity - On October 14, 2025, the net inflow of funds from major investors was 941,700 yuan, while retail investors experienced a net outflow of 3,077,100 yuan, indicating varied investor sentiment [3]